Synbio International Inc (OTC:SYIN) Stock Jumps As Company’s AI-Powered Facial Screening Technology Set for Clinical Trials
Innovative companies are almost always highly sought after among investors, and one such company that was in the news cycle yesterday was Synbio International Inc (OTC:SYIN). The company was in significant focus yesterday after it made an announcement about one of its AI-powered offerings related to the treatment of depressive symptoms.
The Announcement
Synbio International announced yesterday that it was going to have clinical trials for the purpose of validating its innovative AI-backed facial analysis software meant for performing non-invasive screening for the detection of depressive symptoms. In the news release, the company stated that the forward-thinking AI digital health company FacialDx Inc. had developed the leading-edge technology. The technology could eventually help in making a major breakthrough in the realm of identification of mental health problems at an early stage.
Key Details
The company announced that it already had a clinical Trial License with FacialDx in place, and thanks to that, Synbio International will embrak on the trial to test the accuracy, scalability, and reliability of the technology. If the trial proves to be successful, Synbio International would then conduct a larger validation trial soon after. It may be a good time to keep an eye on the Synbio International stock this week.
In a joint statement, CEOs Claudio Solitario of Synbio and Doug Benoit of FacialDx shared their excitement about the partnership:
“We are thrilled to announce our collaboration to validate and commercialize NIMS. Synbio and FacialDx share a deep-seated vision of harnessing artificial intelligence to assist in the screening of mental health conditions. Designed for seamless integration into clinical practices and corporate platforms, NIMS has the potential to make mental health evaluations more accessible than ever before. By helping to break down the barriers to early diagnosis by early detection, this groundbreaking innovation can redefine the future of mental healthcare, profoundly transforming the lives of patients, their families and friends”.
Technicals
| +/- EMA(20) | 0.0023 (+26.09%) |
| +/- SMA(50) | 0.0022 (+31.82%) |
| +/- SMA(200) | 0.0035 (-17.14%) |
| 5-Day Perf. | +3.57% |
| 1-Month Perf. | +61.11% |
| 3-Month Perf. | -9.38% |
| 6-Month Perf. | -3.33% |
| YTD Perf. | +70.59% |
| 1-Year Perf. | -19.44% |
| RSI(14) | 56.16 |
| ATR(14) | – |
| ADX(14) | 31.44 |
